Evidence map›Paper›PMID 24356715›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.

Paul J Grant, Lisa A Joseph, Cristan A Farmer, David A Luckenbaugh, Lorraine C Lougee, Carlos A Zarate, Susan E Swedo

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00251303 (An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole), which is not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00251303 phase2completednot on this map

An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent

TypeinterventionalSponsorNational Institute of Mental Health (NIMH)Ran2005 to 2012Enrolled78ConditionsObsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger DisorderArmsRiluzole, Placebo
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.Journal of the American Academy of Child and Adolescent Psychiatry · 2015
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Pharmacotherapeutic Strategies and New Targets in OCD.Current topics in behavioral neurosciences · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Paul J GrantPediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Lisa A JosephPediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Cristan A FarmerPediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
David A LuckenbaughExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Lorraine C LougeePediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Susan E SwedoPediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · USNational Institute of Mental Health · US

Funding

Evaluation and Treatment of Obsessive Compulsive and Related DisordersZIAMH002666 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI SWEDO, SUSAN · 2009 to 2019
$7.6M
Trial of a Glutamate Antagonist in the Treatment of OCD and Autistic DisordersZIAMH002913 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI SWEDO, SUSAN · 2009 to 2012
$1.4M
Intramural NIH HHS ZIA MH002913PHS HHS 1ZIAMH002913
6 · The paper itself

Abstract

Many children with childhood-onset obsessive-compulsive disorder (OCD) fail to respond adequately to standard therapies. Evidence from preclinical and clinical studies suggests that the glutamatergic neurotransmitter system might be an alternative treatment target. This study examined the efficacy of riluzole, a glutamatergic modulator, as an adjunctive therapy for children with treatment-resistant OCD. In a 12-week, double-blind, placebo-controlled study, 60 treatment-resistant children and adolescents (mean age=14.5 ± 2.4 years), with moderate to severe OCD (mean Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)=28.2 ± 3.7), 17 of whom also had concomitant autism spectrum disorder, were randomized to receive riluzole (final dose of 100 mg/day) or placebo in addition to the existing treatment regimen. Fifty-nine subjects completed the randomized trial. Primary outcome measures were changes on the CY-BOCS, the Clinical Global Impressions Scale, and the Children's Global Assessment Scale. Riluzole was fairly well tolerated, although it was associated with one case of pancreatitis and five instances of slight increases in transaminases. All subjects showed significant reductions in CY-BOCS scores during treatment; however, there was no significant difference between placebo and riluzole on any of the primary or secondary outcome measures. The study failed to demonstrate superiority of riluzole over placebo as an adjunctive treatment for children with childhood-onset OCD. However, future studies may show benefits for less treatment-refractory children with fewer concomitant medications.

Indexed as

AdolescentAge of OnsetChild Development Disorders, PervasiveComorbidityDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychotropic DrugsRiluzoleTreatment OutcomePsychotropic DrugsRiluzole

Identifiers

PMID24356715
PMCPMC3988548
OpenAlexW2001336540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.